{"filings":[{"id":2171436,"accession_number":"0001628280-26-055484","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2026-08-11T10:59:00+00:00","items":["2.02","9.01"],"status":"ready","headline":"Shattuck Labs Q2 net loss widens to $15.2M; cash $208M; SL-325 Phase 1 positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2026 net loss $15.2M ($0.12/sh) vs $12.5M ($0.24/sh) in Q2 2025; R&D $11.7M, G&A $4.5M.","Cash, equivalents and short-term investments $208.3M at 6/30/26, expected to fund operations into 2029.","SL-325 Phase 1: 3.7% ADA, >3-month DR3 blockade at ≥1mg/kg, favorable safety, no DR3 agonism.","RECEPTIVE-CD1 Phase 2b Crohn's starts Q3 2026: ~232 pts, primary endpoint endoscopic response at 12 wks, data 1H 2028.","SL-846 bispecific (DR3 x IL-23R) in IND-enabling tox; Phase 1 healthy volunteer trial expected 2027; poster at UEGW Oct 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":982636,"accession_number":"0001193125-26-266745","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2026-06-11T12:25:58+00:00","items":["1.01","9.01"],"status":"ready","headline":"Shattuck Labs raises ~$86.25M in underwritten public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offered 10,879,376 shares at $4.00/share and 7,870,624 pre-funded warrants at $3.9999 each.","Underwriters' 30-day option for 2,812,500 additional shares exercised in full on June 10, 2026.","Total gross proceeds approximately $86.25 million; expected close June 11, 2026.","Underwriting led by Leerink, J.P. Morgan, Piper Sandler, and Cantor Fitzgerald.","Pre-funded warrants immediately exercisable; beneficial ownership cap of 4.99%/9.99% applies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":946316,"accession_number":"0001193125-26-263831","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2026-06-09T20:28:58+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"SL-325 Phase 1 shows 3.7% ADA, durable DR3 blockade; 96% of warrants exercised for ~$49.3M additional proceeds.","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1: ADA detected in only 3.7% (2/54) of SL-325 recipients; low titer (≤16) with no PK/RO impact.","Complete DR3 occupancy at all doses ≥0.1 mg/kg; PK modeling suggests >3 months blockade at doses ≥1 mg/kg.","No serious TEAEs; all TRAEs Grade 1; no DR3 agonism or lymphocyte proliferation observed.","RECEPTIVE-CD1 Phase 2b in Crohn's expected to start Q3 2026; primary endpoint endoscopic response at Week 12.","Warrant exercise for ~50.6M shares (96% of Aug 2025 placement) yields ~$54.9M gross; cash runway into 2029."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":807998,"accession_number":"0001193125-26-253784","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2026-06-02T21:00:32+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Shattuck Labs shareholders approve equity plan amendment adding 1.69M shares, extend term to 2036","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to 2020 Equity Incentive Plan, increasing share reserve by 1,691,082 shares and extending term to March 23, 2036.","Plan includes automatic annual increase of 4% of outstanding common stock from 2027 to 2030, subject to board discretion.","All three Class III director nominees (Taylor Schreiber, Helen Boudreau, Clay Siegall) elected with over 50M votes each.","Advisory vote on executive compensation passed with 49.85M for, 4.36M against; one-year frequency for future say-on-pay votes selected.","Ratification of KPMG as independent auditor passed with 64.8M votes for, 7,317 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94650,"accession_number":"0001628280-26-031643","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Shattuck Labs Q1 net loss $14.8M; Phase 1 SL-325 enrollment complete, data Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $90.4M as of March 31, 2026, up from $60.9M a year ago; cash runway into 2029 assuming warrant exercise.","Phase 1 trial of SL-325 (DR3 blocking antibody) enrollment complete; safety, PK, PD data expected Q2 2026.","Phase 2 trial in Crohn's disease expected to initiate Q3 2026, subject to positive Phase 1 data and regulatory alignment.","Net loss $14.8M ($0.13 per share) vs $13.7M ($0.27) in Q1 2025; R&D expenses $10.9M vs $9.9M.","Lead bispecific DR3 antibody in IND-enabling activities; target disclosure and preclinical data expected Q2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107175,"accession_number":"0001628280-26-014987","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Shattuck Labs reports FY2025 net loss $48.8M; SL-325 Ph1 data expected Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for FY2025 was $48.8M ($0.70/diluted share), vs $75.4M ($1.49) in FY2024.","Cash and investments at Dec 31, 2025 were $78.1M; after $21.4M ATM raise in Q1 2026, pro forma cash ~$94.5M.","SL-325 Phase 1 in healthy volunteers nearly complete; data expected Q2 2026, Phase 2 in Crohn's planned Q3 2026.","R&D expenses fell to $35.3M from $67.2M, driven by discontinuation of SL-172154 program.","Michael Choi, M.D., appointed VP of Clinical Development; cash runway guidance extended into 2029."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107174,"accession_number":"0001193125-26-039488","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Shattuck Labs 2026 annual meeting set for May 28; proxy deadlines revised","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting scheduled for May 28, 2026; proxy materials to be distributed later.","Stockholder proposals under Rule 14a-8 must be received by Feb 15, 2026.","Director nominations and other proposals under Bylaws must be received Jan 28–Feb 27, 2026.","Revised deadlines due to meeting being more than 30 days before prior year anniversary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107173,"accession_number":"0001193125-26-019682","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2026-01-22T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Shattuck Labs enters $75M ATM equity distribution agreement with Leerink Partners","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Sales Agreement with Leerink Partners for at-the-market offering of up to $75M of common stock.","Shares sold at market prices; company not obligated to sell any shares.","Proceeds to fund ongoing/planned clinical trials and for working capital/general corporate purposes.","Agent commission of up to 3% of gross sales price plus reimbursement of expenses.","Registration statement on Form S-3 declared effective January 21, 2026; prospectus supplement filed January 22, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123509,"accession_number":"0001680367-25-000056","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Shattuck Labs Q3 net loss $10.1M; SL-325 Phase 1 dosing underway; $103M private placement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["First participants dosed in Phase 1 trial of SL-325 (DR3 antagonist) in healthy volunteers; SAD/MAD enrollment expected Q2 2026.","Closed $103M private placement in August 2025; cash runway extended into 2029 assuming full warrant exercise.","Net loss $10.1M ($0.14/sh) vs $16.6M ($0.33/sh) in Q3 2024; R&D expenses down to $7.6M from $16.3M.","Appointed Dan Baker, M.D. and Mona Ashiya, Ph.D. to Board of Directors in August 2025.","Cash and equivalents $86.1M as of Sept 30, 2025; funding to support SL-325 through Phase 2 and other milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":1000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123508,"accession_number":"0001680367-25-000060","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K/A","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Shattuck Labs doses first volunteers in Phase 1 trial of SL-325; closes $103M private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First participants dosed in Phase 1 trial of SL-325, a DR3 antagonist antibody, in healthy volunteers.","Closed private placement of up to $103M in August 2025; cash expected to fund operations into 2029.","Net loss of $10.1M ($0.14 per share) vs $16.6M ($0.33) in Q3 2024; R&D expenses down to $7.6M.","Cash and investments at $86.1M as of Sep 30, 2025, supporting pipeline advancement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140186,"accession_number":"0001193125-25-188078","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2025-08-26T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Shattuck closes up to $103M private placement, appoints two new directors, cash runway into 2029","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed private placement of up to ~$103M led by OrbiMed; net proceeds to fund SL-325 through Phase 2 trials.","Pro forma cash, assuming full warrant exercise, expected to fund operations into 2029.","Appointed Dr. Daniel Baker (independent director) and Dr. Mona Ashiya (OrbiMed designee) to Board.","Directors Tyler Brous, Carrie Brownstein, Michael Lee, Kate Sasser resigned upon closing.","SL-325 (DR3 blocking antibody) IND cleared; Phase 1 trial to start this quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140185,"accession_number":"0001680367-25-000044","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Shattuck Labs Q2 net loss narrows to $12.5M; IND submitted for SL-325 Phase 1, $103M private placement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $12.5M ($0.24/sh) vs $21.6M ($0.42/sh) YoY; R&D costs fell to $8.7M from $19.2M.","Cash $50.5M as of June 30; up to $103M from oversubscribed private placement led by OrbiMed to fund ops into 2029.","Submitted IND for SL-325 (DR3 blocking antibody) in July 2025; clearance expected Q3 2025; first dosing in Phase 1 expected Q3 2025.","Phase 1 trial in healthy volunteers to complete Q2 2026; funds expected to support operations into 2029."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140184,"accession_number":"0001193125-25-173010","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Shattuck Labs raises up to $103M in oversubscribed private placement to fund SL-325 Phase 2 trials","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initial $46M gross proceeds from shares/pre-funded warrants; up to $57M additional if common warrants fully exercised.","OrbiMed led round; participation from Adage Capital, Redmile Group, Coastlands Capital, Prosight Capital, NextBio Capital.","Proceeds to fund SL-325 Phase 1 (start Q3 2025) and multiple Phase 2 trials including IBD; cash runway into 2029.","Common warrants ($1.0846 exercise) expire 30 days after public Phase 1 data announcement, expected in 2026.","Closing contingent on IND clearance for SL-325; certain investors receive board designation rights at closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140183,"accession_number":"0001193125-25-159387","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2025-07-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Shattuck Labs stockholders elect Class II directors, ratify KPMG as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Neil Gibson, George Golumbeski, and Kate Sasser elected as Class II directors with 29.6M–30.4M votes for each.","Ratification of KPMG LLP as independent auditor passed with 41.0M votes for, 5,482 against, 5,050 abstentions.","Annual Meeting held July 10, 2025; 47.9M shares entitled to vote as of May 14 record date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157829,"accession_number":"0001680367-25-000030","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Shattuck Labs Q1 net loss $13.7M, cash $60.9M; SL-325 IND filing expected Q3 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $13.7M ($0.27 per share) for Q1 2025 compared to $18.5M ($0.37 per share) in Q1 2024.","Cash and equivalents of $60.9M as of Mar 31, 2025, expected to fund operations into 2027.","SL-325 IND filing expected in Q3 2025; Phase 1 SAD portion first patient in Q3 2025, enrollment complete Q2 2026.","R&D expenses decreased to $9.9M from $16.3M YoY; G&A expenses decreased to $4.5M from $4.9M.","Wind-down activities for discontinued oncology programs substantially completed."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176207,"accession_number":"0001680367-25-000009","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Shattuck Labs Q4 2024 net loss $18.7M; advances SL-325 DR3 antibody to Phase 1","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $73.0M as of Dec 31, 2024; expected to fund operations into 2027.","Net loss Q4 2024 $18.7M ($0.37/share) vs $17.7M ($0.41) Q4 2023; FY loss $75.4M vs $87.3M.","R&D expenses $15.4M Q4; full year $67.2M down from $74.3M due to termination of SL-172154 program.","SL-325 DR3 blocking antibody on track for IND filing in Q3 2025; Phase 1 enrollment expected complete Q2 2026.","Preclinical NHP data at ECCO showed favorable safety, full receptor occupancy, no DR3 agonism."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193098,"accession_number":"0001680367-24-000050","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Shattuck Labs Q3 net loss $16.7M; shifts focus to SL-325 DR3 antibody; cash runway into 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $16.7M ($0.33 per share) vs $27.5M in Q3 2023; no revenue (pre-revenue stage).","Strategic pivot: discontinuing SL-172154; prioritizing first-in-class DR3 antagonist SL-325 with IND filing expected Q3 2025.","Cash and investments ~$90.1M as of Sept 30, 2024, expected to fund operations into 2027.","Substantially completed restructuring (workforce reduction) tied to SL-172154 discontinuation.","R&D expenses fell to $16.3M from $24.2M; G&A expenses dropped to $4.6M from $5.1M YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":5721000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193097,"accession_number":"0001193125-24-229480","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2024-10-01T23:59:59+00:00","items":["1.02","2.05","8.01","9.01"],"status":"ready","headline":"Shattuck Labs discontinues SL-172154, cuts 40% workforce, pivots to DR3 antagonist SL-325","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Discontinued SL-172154 after interim OS data showed only modest improvement vs azacitidine monotherapy in TP53m AML/HR-MDS.","Plans to focus on SL-325, a first-in-class DR3 antagonist antibody for IBD; IND filing expected Q3 2025.","Approximately 40% workforce reduction; expects restructuring charges of $1.5M-$1.75M in Q4 2024.","Cash runway extended into 2027, with $105.3M cash, cash equivalents and investments as of June 30, 2024.","Mutually terminated collaboration with Ono Pharmaceutical; no future reimbursements, milestones, or royalties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209471,"accession_number":"0001680367-24-000038","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Shattuck Labs Q2 net loss $21.5M; SL-172154 shows 67% ORR in HR-MDS trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $21.5M ($0.42 per share) vs $21.3M ($0.50 per share) Q2 2023.","Cash and investments $105.3M as of June 30, 2024, down from $117.2M a year ago.","SL-172154 in frontline HR-MDS: 67% ORR, 58% CR/marrow CR rate; median OS not reached.","Randomized Part D enrollment initiated in frontline HR-MDS (1:1:1 vs AZA alone).","Cash runway into 2026, beyond Phase 1 trial results."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":2724000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227538,"accession_number":"0001193125-24-161087","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Shattuck Labs reports 67% ORR in HR-MDS, 43% in TP53m AML from SL-172154 Phase 1B","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Observed 67% ORR in frontline HR-MDS patients (24 treated), with 42% complete remission rate; median survival not yet reached.","In 21 frontline TP53m AML patients, ORR 43% with 29% CR; median survival not reached; 5 patients bridged to transplant.","Manageable safety: no grade 3+ IRRs with dexamethasone premedication; no hemolytic anemia; deaths unrelated to SL-172154.","Company focusing later-stage development on HR-MDS and TP53m AML; no further PROC development due to competitive landscape.","Enrollment underway for randomized controlled HR-MDS cohort; regulatory discussions expected later this year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227535,"accession_number":"0001193125-24-159174","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K/A","filed_at":"2024-06-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Shattuck Labs appoints new directors to board committees","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Kate Sasser appointed to Nominating and Corporate Governance Committee effective June 11, 2024.","Dr. Clay Siegall appointed to Compensation Committee effective June 11, 2024.","Both were previously appointed to the Board on March 4, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227537,"accession_number":"0001193125-24-158369","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2024-06-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Shattuck Labs reports 2024 annual meeting vote results; all proposals approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Tyler Brous elected as Class I director with 35,243,095 votes for; 130,433 withheld; 6,153,480 broker non-votes.","Carrie Brownstein, M.D. elected with 31,974,536 votes for; 3,398,585 withheld; 6,153,887 broker non-votes.","Michael Lee elected with 31,970,466 votes for; 3,402,655 withheld; 6,153,887 broker non-votes.","Ratification of KPMG LLP as independent auditor: 41,479,667 for, 19,768 against, 27,573 abstain (no broker non-votes)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227536,"accession_number":"0001680367-24-000024","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Shattuck Q1 net loss $18.5M, cash $114.6M; expects data at EHA June 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $18.5M ($0.37 per share) vs $20.7M ($0.49) in Q1 2023; R&D $16.3M, G&A $4.9M.","Cash and investments $114.6M at March 31, 2024, down from $135.5M a year ago; cash runway into 2026.","Phase 1B expansion for TP53m AML completed enrollment; randomized HR-MDS cohort expected Q2 2024; data at EHA June 2024.","Appointed Clay Siegall, Ph.D., and Kate Sasser, Ph.D. to Board of Directors effective March 1, 2024.","Entered collaboration with Ono Pharma for bifunctional fusion proteins in autoimmune/inflammatory diseases."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":1115000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246371,"accession_number":"0001193125-24-056839","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2024-03-04T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Shattuck Labs appoints Dr. Clay Siegall and Dr. Kate Sasser to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointments effective March 1, 2024; board now includes two new independent directors.","Dr. Siegall is CEO/Chairman of Immunome (IMNM) and former CEO/Chairman of Seagen (acquired by Pfizer).","Dr. Sasser is Chief Scientific Officer of Tempus AI and previously led translational research at Genmab and J&J.","Co. expects clinical updates for SL-172154 mid-2024 and plans late-stage/pivotal studies in multiple indications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246370,"accession_number":"0001680367-24-000012","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Shattuck Labs reports Q4 net loss $17.7M, cash $130.6M; SL-172154 data expected mid-2024; Ono deal up to $227M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss $17.7M (Q4 2023) vs $25.4M (Q4 2022); full-year $87.3M vs $101.9M; cash $130.6M at year-end.","Positive Phase 1A/B SL-172154 data in HR-MDS and TP53m AML; completed initial enrollment for expansion cohorts.","Completed Phase 1B SL-172154 + PLD trial in PROC with positive interim data; all mid-2024 updates expected.","Strategic collaboration with Ono Pharma for autoimmune targets; up to $227M in milestones plus tiered royalties.","Completed $50M public offering in Q4 2023; cash runway extended into 2026 beyond Phase 1 readouts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246369,"accession_number":"0001193125-24-032780","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2024-02-13T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Shattuck Labs and Ono Pharma collaborate on fusion proteins; upfront $9M, milestones up to $217.5M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront payment plus research milestones total up to $9M; Ono reimburses all research costs.","Exclusive option for Ono to license compounds after research; exercise triggers up to $217.5M in development, regulatory, and commercial milestones.","Tiered royalties on global net sales: mid-single digit to low double digit percentages per product/country for 10 years.","Parties cannot commercialize products with same mechanism of action globally during the agreement term.","Ono can terminate on 90 days' notice; Shattuck can terminate if Ono abandons development after option exercise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263811,"accession_number":"0001193125-23-302156","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2023-12-22T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Shattuck Labs raises ~$47.5M in public offering and private placement of pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Public offering of 4,651,163 common shares at $6.45/share; private placement of pre-funded warrants for 3,100,823 shares at $6.4499/warrant.","Net proceeds expected to be approximately $47.5 million after underwriting discounts and expenses.","Proceeds to fund development of pipeline candidate SL-172154 and for working capital.","Closing expected on December 26, 2023.","Evercore Group L.L.C. acted as representative of the underwriters for the public offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263810,"accession_number":"0001193125-23-300388","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2023-12-21T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Shattuck reports early efficacy for SL-172154 in frontline HR-MDS and TP53m AML","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["HR-MDS: 5/14 evaluable patients achieved CR; 4 achieved mCR with hematologic improvement.","TP53m AML: 2/11 evaluable patients achieved CR; 1 patient with CRi proceeded to allo-HCT.","Grade 3/4 AEs related to SL-172154 reported in 14% of TP53m AML and 18% of HR-MDS patients.","Infusion-related reactions most common TEAE; no destructive anemia observed.","Cohorts expanded; additional data expected mid-2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263809,"accession_number":"0001193125-23-293874","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2023-12-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Shattuck reports 79% ORR in frontline HR-MDS and 27% CR/CRi in TP53m AML from SL-172154 trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["79% objective response rate (ORR) with 64% complete response (CR)/marrow CR in 14 evaluable frontline HR-MDS patients.","27% initial CR/CRi in 11 evaluable frontline TP53m AML patients; 5 achieved stable disease with decreasing blasts.","SL-172154 + azacitidine showed acceptable safety; no destructive anemia; most common TEAE was infusion-related reaction.","Cohorts expanding; Shattuck expects next data update by mid-2024.","Monotherapy response in R/R AML patient allowed stem cell transplant; patient remains disease-free."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263808,"accession_number":"0001680367-23-000060","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Shattuck reports Q3 net loss $27.5M; SL-172154 PROC ORR ~27% vs 4% benchmark","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $27.5M ($0.65/share) for Q3 2023 vs $24.6M ($0.58/share) a year ago.","Cash and investments $101.1M as of Sep 30, 2023, sufficient to fund operations through 2024.","SL-172154 + PLD in PROC: 3 partial responses out of 11 evaluable patients (27% ORR), acceptable safety.","Topline data from Phase 1A/B in R/R AML/HR-MDS to be presented at ASH Dec 2023; abstract shows monotherapy response.","Expect to complete enrollment in PROC expansion and frontline HR-MDS cohorts in Q4 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":943000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281019,"accession_number":"0001680367-23-000049","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Shattuck Labs Q2 net loss $21.3M ($0.50/sh); cash $117.2M; SL-172154 trials advancing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $117.2M at June 30, 2023, down from $214.2M a year earlier; runway through end of 2024.","Net loss of $21.3M ($0.50 per share) for Q2 2023 vs. $27.4M ($0.65) in Q2 2022; R&D spend decreased to $18.2M.","Phase 1A PROC monotherapy data presented at ASCO 2023; 3 mg/kg dose selected for combination cohorts.","Enrollment completed in dose-escalation part of Phase 1A/B for SL-172154 in AML/HR-MDS; initial combo data expected Q4 2023.","GADLEN platform: second NHP toxicology study showed inferior B-cell depletion; no IND planned until resolved."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.99,"consensus_revenue_estimate":null,"consensus_revenue_actual":257000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299709,"accession_number":"0001193125-23-152998","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2023-05-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Shattuck Labs shareholders elect directors, ratify KPMG as auditor at 2023 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Helen M. Boudreau elected director: 26,689,880 votes for, 1,007,139 withheld.","Taylor Schreiber elected director: 26,686,925 votes for, 1,010,094 withheld.","Ratification of KPMG LLP as independent auditor: 36,301,756 for, 6,398 against, 4,783 abstentions.","42,460,258 shares entitled to vote; broker non-votes were 8,615,918 on director elections.","No other proposals were submitted; all items approved as recommended by the board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299708,"accession_number":"0001680367-23-000033","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Shattuck Labs reports Q1 net loss $20.7M; cash $135.5M; clinical milestones on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $20.7M ($0.49 per share) vs $24.5M ($0.58 per share) in Q1 2022.","Cash and investments $135.5M at March 31, 2023, expected to fund operations through year-end 2024.","R&D expenses $16.7M (down from $19.2M); G&A $5.1M (flat YoY).","Complete Phase 1A monotherapy data for SL-172154 in PROC to be presented at ASCO June 2023.","Initial Phase 1B combo data (liposomal doxorubicin) expected mid-2023; mirvetuximab combo trial dosed first patients."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":57000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319820,"accession_number":"0001193125-23-067776","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2023-03-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Shattuck Labs: $2.3M at SVB less than 1.7% of total cash; no investment exposure","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Total deposits of ~$2.3M at Silicon Valley Bank, less than 1.7% of cash & equivalents and investments.","No cash equivalents or investments held at SVB; another institution custodies third-party investments in US government obligations.","Company does not believe these investments are directly exposed to SVB insolvency consequences.","SVB was taken over by California banking regulator on March 10, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319819,"accession_number":"0001680367-23-000017","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2023-02-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Shattuck Labs reports Q4 2022 net loss of $25.4M, discontinues SL-279252 program","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2022 $25.4M ($0.60/share) vs net income $7.8M in Q4 2021; full-year net loss $101.9M.","Cash and investments $161.3M at Dec 31, 2022, down from $268.8M; cash runway into H2 2024.","Discontinued SL-279252 program after Phase 1 failed to meet 20% response rate threshold.","Initiated Phase 1B trial of SL-172154 + mirvetuximab soravtansine in ovarian cancer; dosed first patients with azacitidine in AML/HR-MDS.","Appointed Dr. George Fromm as CSO of ARC platform and Dr. Suresh de Silva as CSO of GADLEN platform."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":652000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338030,"accession_number":"0001680367-22-000031","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Shattuck Labs Q3 net loss $24.6M; cash $185.1M; SL-172154 trial enrollment complete","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $24.6M ($0.58/share) vs $17.4M ($0.41/share) in Q3 2021, driven by higher R&D and G&A costs.","Cash and investments $185.1M as of Sep 30, 2022, down from $268.8M at Dec 31, 2021; cash runway into H2 2024.","Completed enrollment in Phase 1 monotherapy dose-escalation of SL-172154 in platinum-resistant ovarian cancer; final data expected midyear 2023.","First patient dosed in Phase 1B combination trial of SL-172154 with liposomal doxorubicin in ovarian cancer; initial data expected midyear 2023.","R&D expenses $18.9M (up 25% YoY); G&A $6.6M (up 53% YoY, including $1.4M litigation settlement)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":262000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355385,"accession_number":"0001680367-22-000021","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2022-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Shattuck Labs Q2 net loss $27.4M; cash runway into H2 2024; SL-172154 combo trials starting","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $214.2M (Dec 2021: $268.8M); operations funded into second half of 2024.","Net loss $27.4M ($0.65/share) vs $23.6M ($0.56) in Q2 2021; R&D expense rose to $23.0M from $14.9M.","SL-172154 dose escalation in ovarian cancer reached 10.0 mg/kg; combo with liposomal doxorubicin starts Q3 2022.","Phase 1A/B of SL-172154 in AML/HR-MDS enrolling; initial monotherapy and combo data expected 1H 2023.","New clinical candidate from ARC or GADLEN platform expected to be announced in second half of 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":50000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355384,"accession_number":"0001193125-22-206671","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2022-07-29T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Shattuck Labs enters $75M at-the-market equity offering program with SVB Securities","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $75M of common stock may be sold from time to time through Agent SVB Securities in ATM offerings.","Agent receives 3.0% commission on gross sales price; Company reimburses certain expenses.","Proceeds intended for pipeline development, working capital, and general corporate purposes.","Company has no obligation to sell any shares; may suspend or terminate the Sales Agreement at any time.","Shares registered under effective S-3 filed March 2022; prospectus supplement filed July 29, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373540,"accession_number":"0001193125-22-172003","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2022-06-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Shattuck Labs 2022 annual meeting elects directors, ratifies KPMG","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Directors Neil Gibson and George Golumbeski elected with ~22.9M votes each; broker non-votes ~10.3M.","KPMG LLP ratified as independent auditor with 35,175,603 votes for, 1,372 against, 321,906 abstentions.","42,378,514 shares of common stock were entitled to vote at the June 7, 2022 meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373539,"accession_number":"0001680367-22-000014","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2022-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Shattuck Labs Q1 net loss $24.5M ($0.58/shr); cash $239.2M; SL-172154 dose escalation ongoing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $24.5M ($0.58 per share) vs $11.8M ($0.28) YoY; R&D expenses $19.2M, up from $10.3M.","Cash & short-term investments $239.2M as of Mar 31, 2022, down from $321.2M a year ago; runway into 2H2024.","Phase 1 dose escalation of SL-172154 in ovarian cancer continues; full monotherapy data expected 1H2023.","Combination trial of SL-172154 with liposomal doxorubicin in ovarian cancer on track to start 2H2022.","Phase 1 trial of SL-279252 in solid tumors enrolling; top-line data expected 2H2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":392235,"accession_number":"0001680367-22-000007","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2022-03-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Shattuck Labs reports Q4 net income $7.8M, cash $268.8M; presents initial clinical data for SL-172154 and SL-279252","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2021 net income $7.8M ($0.18 diluted) vs net loss $12.0M in Q4 2020; full year net loss $45.0M vs $36.6M.","Revenue $30.1M in Q4 (up from $1.3M) due to Takeda collaboration revenue recognition; R&D expenses $16.2M.","Cash $268.8M as of Dec 31, 2021, sufficient into second half 2024.","Initial clinical data for SL-172154 in ovarian cancer showed favorable safety, target occupancy, and CD40 activation; combination trial planned.","SL-279252 showed anti-tumor activity including partial response in ocular melanoma; dose escalation continues to 24 mg/kg."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":410565,"accession_number":"0001680367-21-000062","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2021-11-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Shattuck Labs posts updated investor presentation for SITC; no new data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Updated investor presentation made available on November 12, 2021 for SITC Annual Meeting.","Filing includes only title slide; no clinical or financial data points provided.","Presentation is furnished under Regulation FD and not incorporated by reference."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":410564,"accession_number":"0001680367-21-000052","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2021-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Net loss $17.4M in Q3; cash $290.2M; SL-172154/SL-279252 Phase 1 data; Takeda deal terminated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $17.4M ($0.41/share) vs $11.8M ($1.54/share) in Q3 2020; cash $290.2M, down from $335.4M.","SL-172154 Phase 1 in ovarian cancer well-tolerated with high CD47 occupancy; dose escalation continues to 10mg/kg.","SL-279252 Phase 1 in solid tumors: one confirmed partial response, stable disease in 12 of 43 patients.","Shattuck and Takeda mutually terminated collaboration; Shattuck regains full rights to SL-279252 and SL-115154.","Cash runway sufficient into H2 2024; guidance reduced due to increased SL-172154 clinical and manufacturing costs."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":-61000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":410563,"accession_number":"0001193125-21-311373","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2021-10-28T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Shattuck Labs appoints Dr. Carrie Brownstein to board; George Golumbeski named Chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Josiah Hornblower resigned as director and Chairman effective October 22, 2021; no dispute with company.","Independent director George Golumbeski appointed Chairman of the Board.","Dr. Carrie Brownstein, CMO of Cellectis, appointed as Class I director and to Nominating and Corporate Governance Committee.","Brownstein brings over 15 years of oncology/rare disease drug development experience from Roche, Regeneron, Celgene."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":429370,"accession_number":"0001680367-21-000035","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2021-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Shattuck Labs reports Q2 net loss of $23.6M; pipeline advances with SL-172154 and SL-279252","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $23.6M ($0.56 loss per share) vs $6.2M ($0.81 loss per share) in Q2 2020; revenue negative $4.2M due to Takeda collaboration cost changes.","Cash and investments $304.8M as of June 30, 2021; cash runway expected through 2024, beyond Phase 1 results.","SL-172154 Phase 1 in ovarian cancer: dose escalation at 3.0 mg/kg, plans to advance to 10.0 mg/kg; no dose-limiting toxicities observed.","SL-279252 Phase 1: additional dose cohorts at 12.0 and 24.0 mg/kg based on pharmacodynamic data; SITC abstracts submitted for November 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":-1961000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}